Skip to main content
. 2016 Mar 3;2016(3):CD005008. doi: 10.1002/14651858.CD005008.pub4

Comparison 4. Epirubicin peak dose 110 mg/m2 versus 83 mg/m2.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
4.1 Clinical heart failure 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.06, 15.48]
4.2 Adverse effects other than cardiac damage 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
4.2.1 Anaemia grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 2.91 [0.79, 10.70]
4.2.2 Leukopenia grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 1.06 [0.75, 1.49]
4.2.3 Neutropenia grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.84, 1.31]
4.2.4 Febrile neutropenia grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.47, 1.31]
4.2.5 Thrombocytopenia grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 12.62 [0.71, 223.52]
4.2.6 Nausea/vomiting grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.91 [0.45, 1.82]
4.2.7 Fatigue grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.32 [0.07, 1.60]
4.2.8 Infection grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.79 [0.48, 1.31]
4.2.9 Central nervous system grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 2.91 [0.12, 71.35]
4.2.10 Pulmonary grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 2.91 [0.12, 71.35]
4.2.11 Peripheral neuropathy grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 4.50 [2.37, 8.54]
4.2.12 Hepatotoxicity grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 1.70 [0.50, 5.77]
4.2.13 Hypersensitivity reactions grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 3.88 [1.71, 8.82]
4.2.14 Mucositis grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.48, 2.28]
4.2.15 Pain grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 0.32 [0.01, 7.93]
4.2.16 Arthralgias/myalgias grade 3 or 4 1 1086 Risk Ratio (M‐H, Random, 95% CI) 3.88 [1.31, 11.54]
4.2.17 Treatment‐related death 1 1086 Risk Ratio (M‐H, Random, 95% CI) 2.91 [0.12, 71.35]